Drug intelligence / Profile preview

EIP200

Development stage: Preclinical
Lead developer: CervoMed
Modality: Small Molecules

Overview

EIP200 is a preclinical-stage small molecule therapeutic candidate being developed by CervoMed for the treatment of multiple central nervous system (CNS) disorders. As of early 2026, the specific molecular target and mechanism of action for EIP200 have not been publicly disclosed by the company. It represents a follow-on program to CervoMed's lead asset, neflamapimod, within their neurodegenerative disease portfolio. The drug is currently undergoing early-stage evaluation to determine its potential in addressing CNS-related pathologies.

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on EIP200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EIP200.

Explore the full profile